Episodic Migraine clinical trials

Explore recruiting episodic migraine clinical trials.

Recruiting episodic migraine studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Episodic Migraine trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

C4951009: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention in Children and Adolescents ≥ 6 to <18 years of age

France, Italy, Spain, Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Erenumab in Children (6 to < 12 Years) and Adolescents (12 to < 18 Years) With Episodic Migraine (OASIS PEDIATRIC [EM])

Germany, Portugal, Italy, Belgium, Spain, Hungary +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A multicentre, triple blind, placebo controlled, parallel group study of atorvastatin in episodic migraine (StatinMigEpisodic)

Norway

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3, Multicenter, 12-Week, Double Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atogepant for the Preventive Treatment of Episodic Migraine in Pediatric Subjects 6 to 17 years of age

Sweden, Hungary, Belgium, Denmark, Italy, France +4 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Prevention and Treatment of Episodic migraine by Cabergoline Therapy (PROTECT) A randomized, placebo-controlled, double-blind, investigator-initiated trial

Denmark

Therapeutic confirmatory (Phase III) EU CTIS Study details

OmaMig Pilot: An open-label, phase IIa, single arm pilot study evaluating the potential clinical benefit and safety of omalizumab in adults with episodic migraine.

Norway

Therapeutic exploratory (Phase II) EU CTIS Study details

Episodic Migraine trials by city

Episodic Migraine in Toronto Episodic Migraine in Vancouver Episodic Migraine in Montreal Episodic Migraine in Calgary Episodic Migraine in Edmonton Episodic Migraine in Ottawa Episodic Migraine in Winnipeg Episodic Migraine in Quebec City Episodic Migraine in Hamilton Episodic Migraine in Kitchener Episodic Migraine in London Episodic Migraine in Halifax Episodic Migraine in New York Episodic Migraine in Los Angeles Episodic Migraine in Chicago Episodic Migraine in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease